IP Library Granted Patent US 10,723,758
Granted Patent B2
US 10,723,758 · App. 16/028,790 · Granted Jul 28, 2020

Oxysterols and methods of use thereof

Inventors: Boyd L. Harrison (Princeton Junction, NJ); Gabriel Martinez Botella (Wayland, MA); Albert Jean Robichaud (Cambridge, MA); Francesco G. Salituro (Marlborough, MA)
Assignee: Sage Therapeutics, Inc.
C07J9/00A61K9/0019A61K9/0095A61K9/2063A61K9/4866A61K31/575C07J9/005C07J13/005C07J13/007C07J31/006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,723,758
App. No.
16/028,790
Granted
Jul 28, 2020
Kind
B2
Abstract

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X, Y, R 1 , R 2a , R 2b , R 4a , R 4b , R 5a , R 5b , R 6a , R 6b , R 7 , and R 8 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

Claims (4)

1. A method of inducing sedation or anesthesia, comprising administering to a subject an effective amount of a compound having the following structure:

or a pharmaceutically acceptable salt thereof.

2. A method for modulating an NMDA receptor in a subject having a CNS-related condition, comprising administering to the subject an effective amount of a compound having the following structure:

or a pharmaceutically acceptable salt thereof, wherein the CNS-related condition is obsessive-compulsive disorder, posttraumatic stress disorder, social phobia, Alzheimer's disease and other forms of dementia, eating disorder, schizophrenia, autism spectrum disorders, pain, anti-NMDA receptor encephalitis, Huntington's disease, or Parkinson's disease.

Assignments (3)
CHANGE OF NAME Recorded Mar 17, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075109/0591 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 5, 2025
From: ROBICHAUD, ALBERT JEAN; BOTELLA, GABRIEL MARTINEZ; SALITURO, FRANCESCO G.; HARRISON, BOYD L.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 071333/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2020
From: HARRISON, BOYD L.; MARTINEZ BOTELLA, GABRIEL; ROBICHAUD, ALBERT JEAN; SALITURO, FRANCESCO G.
To: SAGE THERAPEUTICS, INC.
Reel/Frame 053835/0789 →
Continuity (4)
Continuation 15319504
Provisional Application 62107236 · Jan 23, 2015
Provisional Application 62014014 · Jun 18, 2014
Related Publication 20190135854A1 · May 9, 2019
Cited By (4)
US 12,268,697 US 12,331,070 US 12,448,409 US 12,540,157